Every Form 4 that Tenaya Therapeutics, Inc. (TNYA) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TNYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNYA filings page.
Tenaya Therapeutics, Inc. (symbol: TNYA) is the issuer of record for a Form 4 filing submitted to the SEC. Ali Faraz reported acquisition or exercise transactions in this Form 4 filing.
Tenaya Therapeutics, Inc. (TNYA) reported that Chief Executive Officer and director Ali Faraz received equity awards on September 10, 2026. He was granted 732,500 stock options exercisable at $0.6488 per share and 122,000 restricted stock units, all under the Amended and Restated 2021 Equity Incentive Plan, with multi-year vesting schedules.
Tenaya Therapeutics, Inc. (TNYA) reported that Chief Medical Officer Tingley Whittemore received equity awards on September 10, 2026. These include a stock option for 293,000 shares of common stock at an exercise price of $0.6488 per share, vesting monthly over four years, and 49,000 restricted stock units vesting in semiannual installments starting February 15, 2027. Following the RSU grant, Whittemore directly holds 263,073 shares of common stock, including 142,076 shares subject to RSU vesting. No Rule 10b5-1 trading plan is reported.
Tenaya Therapeutics, Inc. director and Chief Executive Officer Ali Faraz reported selling an aggregate 22,232 shares of common stock on 2026-08-17 in four open-market transactions at weighted average prices of about $0.71 per share. Footnotes state each sale covered tax withholding obligations arising from the vesting of restricted stock units granted on February 15, 2023, February 23, 2024, February 6, 2025, and February 3, 2026, respectively. Additional disclosure notes future issuance of 305,956, 295,331, 281,894, and 262,069 shares upon vesting of these restricted stock units.
Tenaya Therapeutics, Inc. Chief Medical Officer Whittemore Tingley reported open-market sales of 7,424 shares of common stock on August 17, 2026 at a weighted average price of $0.7098 per share, with individual trade prices ranging from $0.6820 to $0.7253. Footnotes state these sales were made to cover tax withholding obligations arising from the vesting of restricted stock units granted in 2023, 2024, 2025, and 2026, rather than as discretionary portfolio trades. Related footnotes also note substantial unvested restricted stock units that will be delivered in future, including 108,544, 104,169, 99,169, and 93,076 shares tied to different award dates, plus 6,000 shares acquired under the 2021 Employee Stock Purchase Plan.
Tenaya Therapeutics, Inc. granted Chief Financial Officer Eric J. Hyllengren a stock option covering 1,650,000 shares of common stock with an exercise price of 0.8365 per share. The option was issued under the 2024 Inducement Equity Incentive Plan, vests 25% after one year then monthly until fully vested, and expires on July 12, 2036.
Tenaya Therapeutics director Williams R. Sanders received a grant of stock options for 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were awarded under the company’s 2021 Equity Incentive Plan. They vest in full on May 28, 2027, or earlier if the next annual stockholder meeting occurs before that date, provided Sanders continues as a service provider.
Tenaya Therapeutics director Jeffrey T. Walsh received a stock option grant covering 120,000 shares of common stock at an exercise price of $0.7989 per share. The option was granted under the company’s 2021 Equity Incentive Plan, vests in full on May 28, 2027 (or earlier, before the next annual stockholder meeting), and expires on May 27, 2036. This filing reports an award of options rather than any open-market share purchase or sale.
Tenaya Therapeutics, Inc. director Catherine Stehman-Breen received a grant of stock options covering 120,000 shares of common stock. These options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The option grant was made under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan and will vest in full on May 28, 2027, or earlier on the day immediately before the next annual meeting of stockholders after the grant date, if that comes first, provided she continues as a service provider. The options expire on May 27, 2036, and following this grant she holds 120,000 options of this award.
Tenaya Therapeutics director Deepak Srivastava received a grant of stock options for 120,000 shares of common stock at an exercise price of $0.7989 per share. The options vest in full on May 28, 2027, or earlier immediately before the next annual stockholder meeting, if he continues as a service provider. The options expire on May 27, 2036.
Tenaya Therapeutics director Karah Herdman Parschauer received a stock option grant for 120,000 shares of common stock. The option has an exercise price of $0.7989 per share, expires on May 27, 2036, and will vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant, if she continues as a service provider.
Tenaya Therapeutics, Inc. director June Lee received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The options will vest in full on May 28, 2027, or earlier on the day immediately before the next annual stockholder meeting after the grant date, as long as Lee continues as a service provider to the company. The options expire on May 27, 2036, and following this grant Lee holds 120,000 options in total.
Tenaya Therapeutics, Inc. reported that director Amy L. Burroughs received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share, were granted as compensation under the company’s Amended and Restated 2021 Equity Incentive Plan, and vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant date, if sooner. The options expire on May 27, 2036, and this filing does not reflect any open‑market buying or selling of Tenaya shares.
Tenaya Therapeutics Chief Executive Officer Ali Faraz reported an open-market sale of 3,390 shares of common stock at $0.7934 per share on May 18, 2026. According to the footnotes, the shares were sold to cover tax withholding obligations related to vesting restricted stock units awarded on February 6, 2025.
After this transaction, Faraz directly holds 440,014 shares of Tenaya Therapeutics common stock. The holding figure includes 321,581 shares that will be issued upon future vesting of restricted stock units, underscoring that the reported sale is tied to tax obligations rather than a reduction of long-term equity awards.
Tenaya Therapeutics Chief Medical Officer Tingley Whittemore reported a small share sale primarily tied to taxes. On the reported date, Whittemore sold 3,121 shares of common stock at $0.7936 per share to cover tax withholding obligations related to vesting restricted stock units awarded on January 24, 2025.
After this transaction, Whittemore held 215,497 shares of Tenaya Therapeutics common stock directly, which includes 112,919 shares that will be issued upon future vesting of restricted stock units. The filing reflects a routine, tax-driven disposition rather than a large change in overall ownership.
Tenaya Therapeutics, Inc. SVP of Finance Tomohiro Higa reported an open-market sale of 1,485 shares of common stock on May 18, 2026 at an average price of $0.7932 per share. According to the disclosure, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units granted on August 15, 2024.
After this transaction, Higa directly holds 118,267 shares of Tenaya common stock. This figure includes 67,938 shares that will be issued to him upon future vesting of restricted stock units, indicating that the sale represents a small portion of his overall equity exposure.
Tenaya Therapeutics’ major shareholder entities affiliated with The Column Group reported significant open‑market sales of common stock. Investment funds including The Column Group III, LP and related Opportunity funds sold a combined 4,170,266 shares of Tenaya common stock in indirect transactions.
The sales occurred on February 24 and 25 at weighted average prices of $0.6153 and $0.5624 per share, across multiple trades within disclosed price ranges. A related holding entry shows 49,313,559 shares of common stock held indirectly as of February 24, which reflects a large investment position by these affiliated funds.
Column Group–affiliated investment funds, significant stockholders of Tenaya Therapeutics, reported open-market sales of an aggregate 829,734 shares of Common Stock on February 20 and 23. Reported weighted-average sale prices were about $0.61 per share, within disclosed ranges from $0.573 to $0.63.
The securities are held indirectly through entities including The Column Group III, LP, The Column Group III-A, LP and TCG Opportunity III LPPeter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.
Higa Tomohiro reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 3,469 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 119,752 shares.
Ali Faraz reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 14,862 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 443,404 shares.
Tingley Whittemore reported open-market sale transactions in a Form 4 filing for TNYA. The filing lists transactions totaling 5,160 shares at a weighted average price of $0.64 per share. Following the reported transactions, holdings were 218,618 shares.
Tenaya Therapeutics major shareholder funds affiliated with The Column Group reported open-market sales of common stock.
On February 10, 2026, The Column Group III, LP and The Column Group III-A, LP reported selling 161,422 and 182,295 Tenaya Therapeutics shares, respectively, at a weighted average price of $0.8161, with individual trades between $0.80 and $0.84.
On February 11, 2026, affiliated funds reported additional sales of 1,905,115 and 2,151,458 shares at a weighted average price of $0.6808, with trades between $0.65 and $0.80. After these transactions, one affiliated fund reported indirectly holding 49,313,559 Tenaya shares.
Tenaya Therapeutics, Inc. granted new equity awards to SVP, Finance Tomohiro Higa. On February 3, 2026, he received 29,250 shares of common stock in the form of restricted stock units, issued at $0 and bringing his directly held common stock (including unvested RSUs) to 123,221 shares.
Higa also received a stock option for 175,500 shares of common stock with an exercise price of $0.915 per share, expiring on February 2, 2036. The option vests in equal monthly installments over 48 months starting one month after the grant date, while the new RSUs vest in eight equal installments every six months beginning August 15, 2026.
Tenaya Therapeutics, Inc. reported new equity awards to its Chief Medical Officer, Tingley Whittemore. On 02/03/2026, Whittemore received 48,750 restricted stock units under the 2021 Equity Incentive Plan. These RSUs vest 1/8 on August 15, 2026, with additional 1/8 installments every six months until fully vested.
On the same date, Whittemore was also granted a stock option for 318,500 shares of common stock at an exercise price of $0.915 per share, vesting in 48 equal monthly installments starting one month after the grant date. Following these transactions, Whittemore beneficially owned 223,778 shares of common stock, including 134,588 shares underlying RSUs.
Tenaya Therapeutics, Inc. reported an equity award grant to its Chief Executive Officer, Ali Faraz. On February 3, 2026, he received 158,600 shares of common stock in the form of restricted stock units at a price of $0 per share, which will vest in installments beginning August 15, 2026 and then every six months until fully vested. He also received a stock option for 952,250 shares of common stock at an exercise price of $0.915 per share, vesting monthly over four years starting one month after the grant date. Following these grants, he beneficially owned 458,266 shares of common stock, including 369,875 shares underlying restricted stock units, and 952,250 stock options, all held directly.
Tenaya Therapeutics, Inc. (TNYA) reported an insider transaction by its SVP, Finance. On 11/17/2025, the officer sold 1,367 shares of common stock at a price of $1.33 per share, coded as a sale to satisfy obligations. The filing explains that the shares were sold to cover tax withholding related to the vesting of restricted stock units granted on August 15, 2024.
After this transaction, the reporting person beneficially owns 93,971 shares of Tenaya Therapeutics common stock. This total includes 50,470 shares that will be issued upon the vesting of restricted stock units in the future.
Tenaya Therapeutics, Inc. reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 2,877 shares of Tenaya common stock at $1.33 per share. The sale was made to cover tax withholding obligations related to the vesting of restricted stock units that were originally granted on January 24, 2025.
After this transaction, the officer beneficially owned 169,926 shares of Tenaya common stock, including 85,838 shares that will be issued upon the vesting of restricted stock units. The filing is a routine Form 4 disclosure of insider equity activity.
Tenaya Therapeutics, Inc. reported a routine insider transaction by its Chief Executive Officer, who is also a director. On 11/17/2025, the reporting person sold 3,126 shares of Tenaya Therapeutics common stock at a price of $1.33 per share. According to the filing, these shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units originally awarded on February 6, 2025.
After this tax-related sale, the reporting person beneficially owned a total of 299,666 shares of Tenaya Therapeutics common stock. This total includes 211,275 shares that will be issued upon the future vesting of restricted stock units. The filing indicates that the ownership is held directly by the reporting person.